NCT/Study#

NCT03625037 /

GCT3013-01

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: